Actively Recruiting
Comparing Intravenous Versus Early Oral Antibiotic Treatment for Adults Hospitalized With Gram-Negative Bloodstream Infection
Led by Johns Hopkins University · Updated on 2026-03-11
1030
Participants Needed
11
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the best approach to treat Gram-negative bloodstream infections GN-BSI in hospitalized adults. This trial compares staying on intravenous IV antibiotics for the entire treatment versus starting with IV antibiotics and switching early to oral antibiotics. The goal is to see if early oral treatment is as effective and potentially safer, affecting quality of life and adverse events. Participants will be randomly assigned to one of two groups one group will continue IV antibiotics such as ceftriaxone, cefepime, piperacillin-tazobactam, or meropenem for the full treatment duration. The other group will switch to oral antibiotics like amoxicillin, cephalexin, ciprofloxacin, or trimethoprim-sulfamethoxazole as soon as possible after blood culture, but no later than five days after. Treatment continues until completion in both groups. During the study, patients will be monitored for outcomes including the Desirability of Outcome Ranking DOOR at 30 days, mortality, infection recurrence, length of hospital stay, and treatment-related side effects. Follow-up includes quality of life interviews and tracking of adverse events. The trial lasts through the antibiotic course with assessments at day 30 to evaluate and compare treatment impacts.
CONDITIONS
Brief Title
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
Research Team
P
Pranita D Tamma, MD, MHS
S
Sara E Cosgrove, MD, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here